The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Engineered Cell‐Membrane‐Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity
Open accessAbstract
The recent success of immunotherapies has highlighted the power of leveraging the immune system in the fight against cancer. In order for most immune‐based therapies to succeed, T cell subsets with the correct tumor‐targeting specificities must be mobilized. When such specificities are lacking, providing the immune system with tumor antigen material for processing and presentation is a common strategy for stimulating antigen‐specific T cell populations. While straightforward in principle, experience has shown that manipulation of the antigen presentation process can be incredibly complex, necessitating sophisticated strategies that are difficult to translate. Herein, the design of a biomimetic nanoparticle platform is reported that can be used to directly stimulate T cells without the need for professional antigen‐presenting cells. The nanoparticles are fabricated using a cell membrane coating derived from cancer cells engineered to express a co‐stimulatory marker. Combined with the peptide epitopes naturally presented on the membrane surface, the final formulation contains the necessary signals to promote tumor antigen‐specific immune responses, priming T cells that can be used to control tumor growth. The reported approach represents an emerging strategy that can be used to develop multiantigenic, personalized cancer immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Hu, C.-M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106634108 · Cited by 2,433
Self-citationCell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Self-citationNanoparticle biointerfacing by platelet membrane cloaking
Hu, C.-M. J., Fang, R. H., Wang, K.-C., Luk, B. T., Thamphiwatana, S., Dehaini, D., Nguyen, P., Angsantikul, P., Wen, C. H., Kroll, A. V., et al. (2015) · Nature · doi:10.1038/nature15373 · Cited by 1,789
Self-citationCancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Fang, R. H., Hu, C.-M. J., Luk, B. T., Gao, W., Copp, J. A., Tai, Y., O’Connor, D. E., & Zhang, L. (2014) · Nano Letters · doi:10.1021/nl500618u · Cited by 1,501
Self-citationExploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Zhang, Q., Dehaini, D., Zhang, Y., Zhou, J., Chen, X., Zhang, L., Fang, R. H., Gao, W., & Zhang, L. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0254-4 · Cited by 958
Self-citationOverwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Differential Requirements for Survival and Proliferation of CD8 Naïve or Memory T Cells
Tanchot, C., Lemonnier, F. A., Pérarnau, B., Freitas, A. A., & Rocha, B. (1997) · Science · doi:10.1126/science.276.5321.2057 · Cited by 856
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 774
A biomimetic nanosponge that absorbs pore-forming toxins
Hu, C.-M. J., Fang, R. H., Copp, J., Luk, B. T., & Zhang, L. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.54 · Cited by 751
Self-citationMechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Thamphiwatana, S., Angsantikul, P., Escajadillo, T., Zhang, Q., Olson, J., Luk, B. T., Zhang, S., Fang, R. H., Gao, W., Nizet, V., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714267114 · Cited by 563
Self-citationTranslational Implications of Tumor Heterogeneity
Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1429 · Cited by 549
Modulating Antibacterial Immunity via Bacterial Membrane-Coated Nanoparticles
Gao, W., Fang, R. H., Thamphiwatana, S., Luk, B. T., Li, J., Angsantikul, P., Zhang, Q., Hu, C.-M. J., & Zhang, L. (2015) · Nano Letters · doi:10.1021/nl504798g · Cited by 509
Self-citationNanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., et al. (2017) · Advanced Materials · doi:10.1002/adma.201703969 · Cited by 501
Self-citationExploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
B16 as a Mouse Model for Human Melanoma
Overwijk, W. W., & Restifo, N. P. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2001s39 · Cited by 434
Pardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Nanoparticle-detained toxins for safe and effective vaccination
Hu, C.-M. J., Fang, R. H., Luk, B. T., & Zhang, L. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.254 · Cited by 342
Self-citationThe History Of Vaccines And Immunization: Familiar Patterns, New Challenges
Stern, A. M., & Markel, H. (2005) · Health Affairs · doi:10.1377/hlthaff.24.3.611 · Cited by 301
Clearance of pathological antibodies using biomimetic nanoparticles
Copp, J. A., Fang, R. H., Luk, B. T., Hu, C.-M. J., Gao, W., Zhang, K., & Zhang, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412420111 · Cited by 296
Self-citationTowards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
Eggermont, L. J., Paulis, L. E., Tel, J., & Figdor, C. G. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.06.007 · Cited by 217
Zhang, Q., Wei, W., Wang, P., Zuo, L., Li, F., Xu, J., Xi, X., Gao, X., Ma, G., & Xie, H.-Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b04955 · Cited by 210
The Roles of IL-12 in Providing a Third Signal for Clonal Expansion of Naive CD8 T Cells
Valenzuela, J., Schmidt, C., & Mescher, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6842 · Cited by 193
Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis.
Liblau, R. S., Tisch, R., Shokat, K., Yang, X., Dumont, N., Goodnow, C. C., & McDevitt, H. O. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.3031 · Cited by 190
Schweitzer, A. N., Borriello, F., Wong, R. C., Abbas, A. K., & Sharpe, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2713 · Cited by 168
Yokoyama, W. M., Koning, F., Kehn, P. J., Pereira, G. M. B., Stingl, G., Coligan, J. E., & Shevach, E. M. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.2.369 · Cited by 157
T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm, W., Thoma, S. J., Leithäuser, F., Mӧller, P., Schirmbeck, R., & Reimann, J. (1998) · PubMed · Cited by 150
Butterfield, L. H., & 易宗毕 (2015) · doi:10.3760/cma.j.issn.1007-9742.2015.11.117 · Cited by 144
The expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 142
Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy
Butler, M. O., & Hirano, N. (2013) · Immunological Reviews · doi:10.1111/imr.12129 · Cited by 132
T Cell-Mediated, IFN-γ-Facilitated Rejection of Murine B16 Melanomas
Böhm, W., Thoma, S. J., Leithäuser, F., Mӧller, P., Schirmbeck, R., & Reimann, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.897 · Cited by 122
Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety
Azoury, S. C., Straughan, D. M., & Shukla, V. (2015) · Current Cancer Drug Targets · doi:10.2174/156800961506150805145120 · Cited by 116
Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy
Turtle, C. J., & Riddell, S. R. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb33a6 · Cited by 100
Nanoparticle-Based Modulation of the Immune System
Fang, R. H., & Zhang, L. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034446 · Cited by 100
Self-citationNanoscale artificial antigen presenting cells for cancer immunotherapy
Rhodes, K. R., & Green, J. J. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.02.016 · Cited by 92
Dendritic cell targeted vaccines: Recent progresses and challenges
Chen, P., Liu, X., Sun, Y., Zhou, P., Wang, Y., & Zhang, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1105415 · Cited by 85
Sckisel, G. D., Mirsoian, A., Minnar, C. M., Crittenden, M. R., Curti, B. D., Chen, J. Q., Blazar, B. R., Borowsky, A. D., Monjazeb, A. M., & Murphy, W. J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0235-4 · Cited by 84
Nanoengineering Approaches to The Design of Artificial Antigen-Presenting Cells
Sunshine, J. C., & Green, J. J. (2013) · Nanomedicine · doi:10.2217/nnm.13.98 · Cited by 81
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 64
Lokhov, P. G., & Balashova, E. E. (2010) · Journal of Cancer · doi:10.7150/jca.1.230 · Cited by 59
Yang, J., Sanderson, N., Wawrowsky, K., Puntel, M., Castro, M. G., & Lowenstein, P. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911587107 · Cited by 56
Lin, J., Chien, C.-Y., Lin, C.-L., Yao, B., Chen, Y., Liu, Y.-H., Fang, Z.-S., Chen, J.-Y., Chen, W.-Y., Lee, N.-N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09049-5 · Cited by 52
Identifying neoantigens for use in immunotherapy
Hutchison, S., & Pritchard, A. L. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9771-6 · Cited by 48
Use of adjuvants for immunotherapy
Circelli, L., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1321725 · Cited by 38
Challenges for cancer vaccine development
Tabi, Z., & Man, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.004 · Cited by 37
Merritt, R. E., Yamada, R. E., Crystal, R. G., & Korst, R. J. (2004) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2003.09.007 · Cited by 29
Chong, H., Hutchinson, G., Hart, I., & Vile, R. G. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.625 · Cited by 17
Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer.
Jacobs, J. J. L., Snackey, C., Geldof, A. A., Characiejus, D., van Moorselaar, R. J. A., & Otter, W. D. (2014) · PubMed · Cited by 16
Fecek, R. J., & Storkus, W. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0071 · Cited by 13
Cited by
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Self-citationRecent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Targeted liposomal drug delivery: a nanoscience and biophysical perspective
Liu, Y., Castro Bravo, K. M., & Liu, J. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00605j · Cited by 294
Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system
Liu, H., Su, Y.-Y., Jiang, X.-C., & Gao, J.-Q. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01252-0 · Cited by 302
Metadata
- Authors
- Jiang, Y., Krishnan, N., Zhou, J., Chekuri, S., Wei, X., Kroll, A. V., Yu, C. L., Duan, Y., Gao, W., Fang, R. H., & Zhang, L.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2020-06-15
- Volume
- 32
- Issue
- 30
- Pages
- e2001808-e2001808
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W3035752162
- Cited by
- 371
- References
- 60
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.